We aim to develop first-in-class and best-in-class macromolecular drugs through original innovation. We have established a globally integrated R&D process with four R&D centers worldwide. We have built up whole-industry-chain technology platforms and mechanism of innovation for macromolecular drugs covering from early discovery to industrialization.